MedPath

rTMS and Multi-Modality Aphasia Therapy for Post-Stroke Aphasia

Not Applicable
Completed
Conditions
Stroke
Aphasia, Non-fluent
Interventions
Device: 1Hz inhibitory rTMS
Behavioral: Multi-Modality Aphasia Therapy (M-MAT)
Device: 1Hz sham rTMS
Registration Number
NCT04901156
Lead Sponsor
University of Calgary
Brief Summary

Many stroke survivors experience aphasia, a loss or impairment of language affecting the production or understanding of speech. One common type of aphasia is known as non-fluent aphasia. Patients with non-fluent aphasia have difficulty formulating grammatical sentences, often producing short word fragments despite having a good understanding of what others are trying to communicate to them. Speech language pathologists (SLPs) play a central role rehabilitating persons with aphasia and administer therapy in an attempt to improve communication skills. Despite standard therapy, approximately 50% of individuals who experience aphasia acutely continue to have language deficits more than 6 months post-stroke.

In most people, Broca's area is dominant in the left side of the brain. Following a left-sided stroke, the right-sided homologue of Broca's area (the pars triangularis), may adopt language function. Unfortunately, reorganizing language to the right side of the brain seems to be less effective than restoring function to the left hemisphere. Repetitive transcranial magnetic stimulation (rTMS), a form of non-invasive brain stimulation, can be used to suppress activity of specific regions in the right side of the brain to promote recovery of function in the perilesional area. Despite preliminary success in existing studies using rTMS in post-stroke aphasia, there is much work to be done to better understand the mechanisms underlying recovery. Responses to rTMS have been positive, yet heterogenous, which may be related to timing of treatments following stroke.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
20
Inclusion Criteria
  • Isolated left middle cerebral artery (MCA) stroke more than 6 months ago (chronic)
  • Stroke type: Ischemic or hemorrhagic
  • Non-fluent aphasia as determined by the Western Aphasia Battery (Fluency < 5)
  • Right-hand dominant prior to stroke
  • English is first or primary language
  • Ability to follow 3-step commands
Read More
Exclusion Criteria
  • Prior stroke to the right frontal lobe
  • Current diagnosis of moderate to severe depression
  • Diagnosis of any other psychiatric condition
  • History of other neurologic disorders (e.g., epilepsy, brain tumor)
  • Contraindication to MRI or TMS (metal in the head or any implanted electrical device)
  • Has received intensive speech therapy within the past 6 months (>8 hours per week)
  • Enrolled in another interventional study
Read More

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Multi-modality aphasia therapy plus 1Hz rTMSMulti-Modality Aphasia Therapy (M-MAT)Chronic stroke patients, receive 10 days of 3.5hrs of multi-modality aphasia therapy (M-MAT) preceded by 20 minutes of 1Hz rTMS delivered at 100% of resting motor threshold over the right pars triangularis.
Multi-modality aphasia therapy plus sham rTMS1Hz sham rTMSChronic stroke patients, receive 10 days of 3.5hrs of multi-modality aphasia therapy (M-MAT) preceded by 20 minutes of sham rTMS is achieved using a sham TMS coil which attenuates the magnetic output of the stimulator by 80%.
Multi-modality aphasia therapy plus 1Hz rTMS1Hz inhibitory rTMSChronic stroke patients, receive 10 days of 3.5hrs of multi-modality aphasia therapy (M-MAT) preceded by 20 minutes of 1Hz rTMS delivered at 100% of resting motor threshold over the right pars triangularis.
Multi-modality aphasia therapy plus sham rTMSMulti-Modality Aphasia Therapy (M-MAT)Chronic stroke patients, receive 10 days of 3.5hrs of multi-modality aphasia therapy (M-MAT) preceded by 20 minutes of sham rTMS is achieved using a sham TMS coil which attenuates the magnetic output of the stimulator by 80%.
Primary Outcome Measures
NameTimeMethod
Change from baseline on the Boston Naming Test at 3 monthsBaseline and 3-month follow-up

Number of spontaneously produced correct responses to a series of line drawings. That is, the number of correctly named images.

Change from baseline on the Boston Naming Test within one week of intervention completionBaseline, within 1 week of completing the 10 day intervention

Number of spontaneously produced correct responses to a series of line drawings. That is, the number of correctly named images.

Secondary Outcome Measures
NameTimeMethod
Trained and Untrained Picture NamingBaseline, within 1 week of completing the 10 day intervention and 3-month follow-up

Number of correctly named pictures from a set of trained nouns, trained verbs, untrained nouns, and untrained verbs

Story Narrative TaskBaseline, within 1 week of completing the 10 day intervention and 3-month follow-up

Retelling of the Cinderella task as a measure of discourse, performance is quantified by number of correct information units.

Patient Health Questionnaire (PHQ-9)Baseline, within 1 week of completing the 10 day intervention and 3-month follow-up

A 9-item questionnaire completed by a caregiver to quickly assess depressive symptoms. The scale ranges from 0 to 27 with higher scores indicating greater endorsement of depressive symptoms.

EuroQoL-5D-5LBaseline, within 1 week of completing the 10 day intervention and 3-month follow-up

Assesses mobility, self-care, usual activities, pain/discomfort and anxiety/depression. The answers given can be converted into EQ-5D index with scores anchored at 0 for death and 1 for perfect health. The EQ-5D also records the patient's self-rated health on a vertical visual analogue scale ranging from 0 to 100 with higher scores indicating higher self-perceived quality of life. This can be used as a quantitative measure of health outcome that reflects the patient's own judgement.

Trial Locations

Locations (1)

Foothills Medical Centre

🇨🇦

Calgary, Alberta, Canada

© Copyright 2025. All Rights Reserved by MedPath